aiolosbio.comHealthcare / BioTech & PharmaFounded: 2023Funding to Date: $247.55MM
Aiolos Bio is revolutionizing treatments for respiratory diseases and immune conditions, aiming to deliver innovative therapies to patients and caregivers. With a seasoned team boasting over 30 FDA approvals, Aiolos Bio is developing effective treatments for asthma, rheumatoid arthritis, and IPF. The company focuses on a groundbreaking anti-TSLP asset, which is expected to enhance efficacy with less frequent dosing than current treatments. Aiolos Bio's mission is to reduce treatment burden and improve patient care through more efficacious therapies.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
10/24/2023 | Series A-1 | $2.55MM | $xx.xx | $436.12MM | Atlas Venture, Bain Capital Life Sciences, Forbion, Ra Capital Management, Sofinnova Investments | |
Price per Share
$xx.xx
Shares Outstanding
2,672,894
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Atlas Venture, Bain Capital Life Sciences, Forbion, Ra Capital Management, Sofinnova Investments
|
||||||
10/24/2023 | Series A-2 | $65MM | $xx.xx | $436.12MM | Atlas Venture, Bain Capital Life Sciences, Forbion, Ra Capital Management, Sofinnova Investments | |
Price per Share
$xx.xx
Shares Outstanding
36,368,035
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Atlas Venture, Bain Capital Life Sciences, Forbion, Ra Capital Management, Sofinnova Investments
|
||||||
10/24/2023 | Series A | $180MM | $xx.xx | $436.12MM | Atlas Venture, Bain Capital Life Sciences, Forbion, Ra Capital Management, Sofinnova Investments | |
Price per Share
$xx.xx
Shares Outstanding
151,067,219
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Atlas Venture, Bain Capital Life Sciences, Forbion, Ra Capital Management, Sofinnova Investments
|